C.Q. Pharmaceutical Holding Co., Ltd. Logo

C.Q. Pharmaceutical Holding Co., Ltd.

000950.SZ

(2.8)
Stock Price

5,58 CNY

0.59% ROA

3.37% ROE

26.6x PER

Market Cap.

10.092.571.200,00 CNY

248.21% DER

0.86% Yield

0.48% NPM

C.Q. Pharmaceutical Holding Co., Ltd. Stock Analysis

C.Q. Pharmaceutical Holding Co., Ltd. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

C.Q. Pharmaceutical Holding Co., Ltd. Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's low PBV ratio (0.8x) suggests it's undervalued, making it an attractive opportunity for investors.

2 Revenue Growth

This company's revenue has experienced steady growth over the last five years, indicating a reliable and prosperous financial trajectory.

3 Assets Growth

Over the past five years, this company's revenue has consistently increased, demonstrating a robust financial performance that makes it an appealing opportunity.

4 ROE

The stock's ROE falls within an average range (6.93%), demonstrating satisfactory profitability and efficiency in utilizing shareholders' equity.

5 ROA

The stock's ROA (1.2%) indicates that it's doing well in making money from the things it owns. This makes it a good option to invest and make consistent profits.

6 Graham Number

The company's Graham number suggests that its stock price is underestimated, implying that it may present a compelling investment opportunity.

7 Dividend

The company's history of regular dividend distributions in the last three years showcases its ability to generate reliable income for shareholders.

8 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock appears undervalued (448), presenting an attractive investment chance with its intrinsic value surpassing the current market price.

9 DER

The stock is burdened with a heavy load of debt (204%), making it financially unstable and potentially risky for investors.

10 Net Profit Growth

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

11 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

C.Q. Pharmaceutical Holding Co., Ltd. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

C.Q. Pharmaceutical Holding Co., Ltd. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

C.Q. Pharmaceutical Holding Co., Ltd. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

C.Q. Pharmaceutical Holding Co., Ltd. Revenue
Year Revenue Growth
1996 334.116.307
1997 400.012.758 16.47%
1998 388.248.944 -3.03%
1999 382.678.261 -1.46%
2000 386.743.245 1.05%
2001 472.620.629 18.17%
2002 334.290.767 -41.38%
2003 356.217.028 6.16%
2004 288.432.848 -23.5%
2005 333.039.287 13.39%
2006 973.958.094 65.81%
2007 1.023.041.922 4.8%
2008 1.449.450.322 29.42%
2009 2.083.651.187 30.44%
2010 2.078.260.062 -0.26%
2011 2.588.551.186 19.71%
2012 3.322.656.519 22.09%
2013 3.437.228.449 3.33%
2014 2.968.713.281 -15.78%
2015 3.326.469.748 10.75%
2016 2.567.050.724 -29.58%
2017 23.044.600.748 88.86%
2018 25.802.739.160 10.69%
2019 33.843.821.480 23.76%
2020 45.219.570.786 25.16%
2021 62.520.755.302 27.67%
2022 67.829.010.438 7.83%
2023 70.674.817.076 4.03%
2023 80.119.107.345 11.79%
2024 80.388.298.040 0.33%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

C.Q. Pharmaceutical Holding Co., Ltd. Research and Development Expenses
Year Research and Development Expenses Growth
1996 0
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 3.246.139 100%
2013 302.117 -974.46%
2014 0 0%
2015 19.235.075 100%
2016 6.276.846 -206.44%
2017 2.254 -278499.47%
2018 243.393 99.07%
2019 2.850.173 91.46%
2020 2.672.757 -6.64%
2021 10.043.426 73.39%
2022 3.236.184 -210.35%
2023 10.960.969 70.48%
2023 383.333 -2759.39%
2024 26.928.896 98.58%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

C.Q. Pharmaceutical Holding Co., Ltd. General and Administrative Expenses
Year General and Administrative Expenses Growth
1996 28.667.600
1997 27.402.121 -4.62%
1998 26.837.546 -2.1%
1999 22.642.815 -18.53%
2000 25.711.051 11.93%
2001 38.080.819 32.48%
2002 47.014.730 19%
2003 58.768.589 20%
2004 31.624.017 -85.84%
2005 29.791.459 -6.15%
2006 62.919.338 52.65%
2007 46.536.305 -35.2%
2008 48.362.313 3.78%
2009 61.443.259 21.29%
2010 59.698.370 -2.92%
2011 114.616.972 47.91%
2012 91.393.367 -25.41%
2013 68.894.259 -32.66%
2014 49.011.678 -40.57%
2015 119.245.530 58.9%
2016 76.152.070 -56.59%
2017 188.677.686 59.64%
2018 108.379.596 -74.09%
2019 118.980.708 8.91%
2020 189.847.271 37.33%
2021 239.455.440 20.72%
2022 305.909.685 21.72%
2023 3.740.429.922 91.82%
2023 303.297.198 -1133.26%
2024 -1.132.136.655 126.79%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

C.Q. Pharmaceutical Holding Co., Ltd. EBITDA
Year EBITDA Growth
1996 36.866.134
1997 51.635.327 28.6%
1998 50.947.720 -1.35%
1999 51.728.528 1.51%
2000 70.275.667 26.39%
2001 65.519.424 -7.26%
2002 -31.235.333 309.76%
2003 -78.009.654 59.96%
2004 65.552.056 219%
2005 19.507.856 -236.03%
2006 318.624.198 93.88%
2007 248.921.450 -28%
2008 314.865.256 20.94%
2009 338.801.974 7.07%
2010 313.064.756 -8.22%
2011 285.479.478 -9.66%
2012 365.728.340 21.94%
2013 326.155.201 -12.13%
2014 -2.411.771 13623.47%
2015 297.040.007 100.81%
2016 -59.625.934 598.17%
2017 1.776.819.893 103.36%
2018 1.210.587.101 -46.77%
2019 1.761.205.647 31.26%
2020 2.313.896.439 23.89%
2021 3.283.020.217 29.52%
2022 3.144.306.979 -4.41%
2023 2.155.062.168 -45.9%
2023 3.196.738.531 32.59%
2024 2.338.202.520 -36.72%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

C.Q. Pharmaceutical Holding Co., Ltd. Gross Profit
Year Gross Profit Growth
1996 70.223.598
1997 86.590.269 18.9%
1998 84.756.517 -2.16%
1999 69.880.013 -21.29%
2000 68.162.486 -2.52%
2001 67.968.559 -0.29%
2002 -7.546.963 1000.61%
2003 -4.818.953 -56.61%
2004 -6.834.406 29.49%
2005 12.287.000 155.62%
2006 361.822.249 96.6%
2007 367.950.858 1.67%
2008 389.115.379 5.44%
2009 368.022.994 -5.73%
2010 310.975.039 -18.34%
2011 404.937.419 23.2%
2012 503.342.893 19.55%
2013 351.044.264 -43.38%
2014 65.001.669 -440.05%
2015 237.426.771 72.62%
2016 -98.623.238 340.74%
2017 2.128.905.933 104.63%
2018 2.312.046.689 7.92%
2019 3.063.553.676 24.53%
2020 4.234.393.033 27.65%
2021 5.738.426.159 26.21%
2022 5.820.230.684 1.41%
2023 5.376.125.794 -8.26%
2023 6.308.714.786 14.78%
2024 5.658.031.068 -11.5%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

C.Q. Pharmaceutical Holding Co., Ltd. Net Profit
Year Net Profit Growth
1996 10.745.551
1997 25.811.367 58.37%
1998 22.857.547 -12.92%
1999 29.630.202 22.86%
2000 37.236.139 20.43%
2001 4.351.390 -755.73%
2002 -98.435.847 104.42%
2003 -143.492.766 31.4%
2004 7.965.291 1901.48%
2005 -43.824.488 118.18%
2006 82.322.079 153.24%
2007 145.444.648 43.4%
2008 272.746.680 46.67%
2009 204.659.903 -33.27%
2010 132.338.957 -54.65%
2011 90.891.359 -45.6%
2012 121.371.295 25.11%
2013 7.277.834 -1567.68%
2014 -361.474.424 102.01%
2015 -367.224.862 1.57%
2016 -664.464.996 44.73%
2017 1.106.266.191 160.06%
2018 690.667.278 -60.17%
2019 788.015.791 12.35%
2020 884.344.217 10.89%
2021 1.005.444.242 12.04%
2022 952.275.637 -5.58%
2023 15.812.847 -5922.16%
2023 654.956.871 97.59%
2024 540.511.196 -21.17%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

C.Q. Pharmaceutical Holding Co., Ltd. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1996 0
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 1 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 -1 0%
2015 -1 0%
2016 0 0%
2017 1 0%
2018 0 0%
2019 0 0%
2020 1 0%
2021 1 0%
2022 1 0%
2023 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

C.Q. Pharmaceutical Holding Co., Ltd. Free Cashflow
Year Free Cashflow Growth
1999 -194.074.755
2000 -69.429.964 -179.53%
2001 -62.661.077 -10.8%
2002 19.025.566 429.35%
2003 -10.367.407 283.51%
2004 51.225.730 120.24%
2005 86.145.020 40.54%
2006 289.529.099 70.25%
2007 -42.948.788 774.13%
2008 -322.209.986 86.67%
2009 -840.238.689 61.65%
2010 -496.579.868 -69.21%
2011 -313.895.811 -58.2%
2012 -73.032.331 -329.8%
2013 -972.613.267 92.49%
2014 -590.896.073 -64.6%
2015 55.395.402 1166.69%
2016 106.207.536 47.84%
2017 -1.253.403.405 108.47%
2018 -2.009.741.569 37.63%
2019 -618.966.276 -224.69%
2020 253.822.588 343.86%
2021 -239.382.414 206.03%
2022 17.763.285 1447.62%
2023 -37.648.070 147.18%
2023 264.127.706 114.25%
2024 -461.595.008 157.22%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

C.Q. Pharmaceutical Holding Co., Ltd. Operating Cashflow
Year Operating Cashflow Growth
1999 77.858.619
2000 88.939.087 12.46%
2001 11.658.992 -662.84%
2002 40.430.432 71.16%
2003 -2.685.009 1605.78%
2004 58.297.500 104.61%
2005 90.148.531 35.33%
2006 297.730.238 69.72%
2007 0 0%
2008 0 0%
2009 247.738.653 100%
2010 10.978.624 -2156.55%
2011 159.877.668 93.13%
2012 349.298.218 54.23%
2013 402.367.200 13.19%
2014 5.738.571 -6911.63%
2015 190.114.550 96.98%
2016 247.546.082 23.2%
2017 -1.101.982.875 122.46%
2018 -1.705.762.262 35.4%
2019 202.411.337 942.72%
2020 631.986.342 67.97%
2021 250.164.875 -152.63%
2022 285.828.791 12.48%
2023 0 0%
2023 508.534.274 100%
2024 -422.028.100 220.5%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

C.Q. Pharmaceutical Holding Co., Ltd. Capital Expenditure
Year Capital Expenditure Growth
1999 271.933.374
2000 158.369.051 -71.71%
2001 74.320.069 -113.09%
2002 21.404.865 -247.21%
2003 7.682.398 -178.62%
2004 7.071.769 -8.63%
2005 4.003.511 -76.64%
2006 8.201.138 51.18%
2007 42.948.788 80.9%
2008 322.209.986 86.67%
2009 1.087.977.342 70.38%
2010 507.558.492 -114.36%
2011 473.773.479 -7.13%
2012 422.330.549 -12.18%
2013 1.374.980.467 69.28%
2014 596.634.644 -130.46%
2015 134.719.147 -342.87%
2016 141.338.546 4.68%
2017 151.420.530 6.66%
2018 303.979.307 50.19%
2019 821.377.613 62.99%
2020 378.163.753 -117.2%
2021 489.547.289 22.75%
2022 268.065.505 -82.62%
2023 37.648.070 -612.03%
2023 244.406.568 84.6%
2024 39.566.908 -517.7%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

C.Q. Pharmaceutical Holding Co., Ltd. Equity
Year Equity Growth
1996 49.146.651
1997 100.693.031 51.19%
1998 102.848.438 2.1%
1999 409.980.875 74.91%
2000 428.107.015 4.23%
2001 425.746.980 -0.55%
2002 329.078.737 -29.38%
2003 185.585.971 -77.32%
2004 197.451.263 6.01%
2005 445.156.070 55.64%
2006 529.579.970 15.94%
2007 744.171.141 28.84%
2008 984.192.061 24.39%
2009 2.288.341.074 56.99%
2010 2.384.960.062 4.05%
2011 2.512.550.858 5.08%
2012 2.431.833.787 -3.32%
2013 2.437.555.744 0.23%
2014 2.074.674.015 -17.49%
2015 1.713.098.317 -21.11%
2016 1.043.342.852 -64.19%
2017 7.251.786.363 85.61%
2018 8.107.634.819 10.56%
2019 8.861.666.987 8.51%
2020 10.480.580.603 15.45%
2021 11.766.543.627 10.93%
2022 12.710.392.096 7.43%
2023 15.446.725.961 17.71%
2023 15.507.364.550 0.39%
2024 15.715.181.650 1.32%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

C.Q. Pharmaceutical Holding Co., Ltd. Assets
Year Assets Growth
1996 141.863.279
1997 268.554.542 47.18%
1998 327.313.560 17.95%
1999 651.570.982 49.77%
2000 832.111.795 21.7%
2001 996.867.796 16.53%
2002 905.674.641 -10.07%
2003 711.521.867 -27.29%
2004 700.944.377 -1.51%
2005 978.888.833 28.39%
2006 1.051.721.732 6.93%
2007 1.206.906.538 12.86%
2008 2.490.701.109 51.54%
2009 3.728.360.956 33.2%
2010 4.106.951.008 9.22%
2011 4.325.226.920 5.05%
2012 5.183.289.425 16.55%
2013 6.549.735.426 20.86%
2014 6.830.931.720 4.12%
2015 6.086.827.832 -12.22%
2016 5.460.168.165 -11.48%
2017 15.204.887.687 64.09%
2018 20.114.884.429 24.41%
2019 25.479.952.289 21.06%
2020 42.432.466.239 39.95%
2021 49.700.081.320 14.62%
2022 57.191.648.432 13.1%
2023 65.052.424.160 12.08%
2023 63.523.679.581 -2.41%
2024 66.247.763.087 4.11%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

C.Q. Pharmaceutical Holding Co., Ltd. Liabilities
Year Liabilities Growth
1996 92.716.627
1997 167.861.511 44.77%
1998 224.465.121 25.22%
1999 241.590.107 7.09%
2000 404.004.779 40.2%
2001 571.120.815 29.26%
2002 576.595.904 0.95%
2003 525.935.896 -9.63%
2004 503.493.114 -4.46%
2005 533.732.762 5.67%
2006 522.141.761 -2.22%
2007 462.735.397 -12.84%
2008 1.506.509.047 69.28%
2009 1.440.019.882 -4.62%
2010 1.721.990.946 16.37%
2011 1.812.676.062 5%
2012 2.751.455.637 34.12%
2013 4.112.179.681 33.09%
2014 4.756.257.704 13.54%
2015 4.373.729.515 -8.75%
2016 4.416.825.313 0.98%
2017 7.953.101.323 44.46%
2018 12.007.249.608 33.76%
2019 16.618.285.302 27.75%
2020 31.951.885.635 47.99%
2021 37.933.537.693 15.77%
2022 44.481.256.335 14.72%
2023 49.605.698.199 10.33%
2023 48.016.315.030 -3.31%
2024 50.466.027.843 4.85%

C.Q. Pharmaceutical Holding Co., Ltd. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
45.79
Net Income per Share
0.22
Price to Earning Ratio
26.6x
Price To Sales Ratio
0.13x
POCF Ratio
13.35
PFCF Ratio
19.71
Price to Book Ratio
0.89
EV to Sales
0.4
EV Over EBITDA
13.64
EV to Operating CashFlow
42.18
EV to FreeCashFlow
62.29
Earnings Yield
0.04
FreeCashFlow Yield
0.05
Market Cap
10,09 Bil.
Enterprise Value
31,90 Bil.
Graham Number
5.71
Graham NetNet
-5.92

Income Statement Metrics

Net Income per Share
0.22
Income Quality
1.99
ROE
0.03
Return On Assets
0.01
Return On Capital Employed
0.04
Net Income per EBT
0.61
EBT Per Ebit
0.69
Ebit per Revenue
0.01
Effective Tax Rate
0.34

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.07
Operating Profit Margin
0.01
Pretax Profit Margin
0.01
Net Profit Margin
0

Dividends

Dividend Yield
0.01
Dividend Yield %
0.86
Payout Ratio
2.26
Dividend Per Share
0.05

Operating Metrics

Operating Cashflow per Share
0.44
Free CashFlow per Share
0.3
Capex to Operating CashFlow
0.32
Capex to Revenue
0
Capex to Depreciation
0.56
Return on Invested Capital
0.01
Return on Tangible Assets
0.01
Days Sales Outstanding
177.96
Days Payables Outstanding
75.12
Days of Inventory on Hand
45.04
Receivables Turnover
2.05
Payables Turnover
4.86
Inventory Turnover
8.1
Capex per Share
0.14

Balance Sheet

Cash per Share
3,92
Book Value per Share
9,13
Tangible Book Value per Share
8.04
Shareholders Equity per Share
6.59
Interest Debt per Share
17.09
Debt to Equity
2.48
Debt to Assets
0.43
Net Debt to EBITDA
9.33
Current Ratio
1.31
Tangible Asset Value
13,89 Bil.
Net Current Asset Value
6,71 Bil.
Invested Capital
18083603524
Working Capital
13,56 Bil.
Intangibles to Total Assets
0.03
Average Receivables
39,69 Bil.
Average Payables
16,54 Bil.
Average Inventory
8680475402
Debt to Market Cap
2.8

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

C.Q. Pharmaceutical Holding Co., Ltd. Dividends
Year Dividends Growth
2001 0
2008 0 0%
2009 0 0%
2011 0 0%
2012 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

C.Q. Pharmaceutical Holding Co., Ltd. Profile

About C.Q. Pharmaceutical Holding Co., Ltd.

C.Q. Pharmaceutical Holding Co., Ltd. distributes pharmaceutical products. Chongqing Medicines Co., Ltd. was formerly known as Southwest Branch of China Medicine Company. The company was founded in 1950 and is based in Chongqing, China. C.Q. Pharmaceutical Holding Co., Ltd. develops, manufactures, and distributes pharmaceuticals. The company is based in Chongqing, China. C.Q. Pharmaceutical Holding Co., Ltd. operates as a subsidiary of Chongqing Chemical & Pharmaceutical Holding Group Company

CEO
Mr. Wei Liu
Employee
14.485
Address
No 1, Datong Road
Chongqing, 400010

C.Q. Pharmaceutical Holding Co., Ltd. Executives & BODs

C.Q. Pharmaceutical Holding Co., Ltd. Executives & BODs
# Name Age
1 Yi Yin
Accounting Supervisor
70
2 Mr. Yihai Chen
Deputy GM & Non-Independent Director
70
3 Ms. Qinghua Yang
Deputy General Manager
70
4 Mr. Shaohong Li
Executive Deputy GM & Director
70
5 Mr. Wei Liu
GM & Director
70
6 Mr. Tian Qiu
Financial Director, Chief Financial Officer & Board Secretary
70

C.Q. Pharmaceutical Holding Co., Ltd. Competitors